To include your compound in the COVID-19 Resource Center, submit it here.

Selecta shares halved on gout combo readout

Selecta Biosciences Inc. (NASDAQ:SELB) sank $12.17 (54%) to $10.36 after reporting updated data from a Phase II trial of lead candidate SEL-212 to treat chronic, severe gout. The therapy is a non-immunogenic combination of pegsiticase

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE